Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 1,716.98 Million |
| USD 2,884.56 Million | |
| % | |
|
Middle East and Africa Malaria Treatment Market, By Agent (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae, P. Knowlelsi), Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Others), Drug Type (Branded, Generics), Treatment (Antimalarial Drugs, Others), Diagnosis (Rapid Diagnostics, Microscopy, Molecular Diagnostic Tests), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Get Exclusive Sample Copy of this Report Here
Market Analysis and Size
According to the World Health Organization (WHO), there were an estimated 241 million cases of malaria globally in 2020. Malaria is spread through the bite of a female Anopheles mosquito carrying Plasmodium parasites. Fever, tiredness, nausea, and headache are all frequent symptoms. The type of Plasmodium that causes malaria and the geographical area where the illness was acquired determine the treatment options. Additionally, pregnant and breastfeeding women, as well as toddlers, require specific attention. Chloroquine is commonly used to treat malaria patients; however, in cases of chloroquine resistance, different drugs are employed.
Data Bridge Market Research analyses that the Middle East and Africa malaria treatment market was valued at USD 1,716.98 million in 2021 and is expected to reach USD 2,884.56 million by 2029, registering a CAGR of 6.70% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Agent (Plasmodium Falciparum, P. Vivax, P. Ovale, P. Malariae, P. Knowlelsi), Drug Class (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, Others), Drug Type (Branded, Generics), Treatment (Antimalarial Drugs, Others), Diagnosis (Rapid Diagnostics, Microscopy, Molecular Diagnostic Tests), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
|
|
Market Players Covered
|
Actiza Pharmaceutical Private Limited (India), AdvaCare Pharma (US), Ipca Laboratories Ltd. (India), Bliss GVS Pharma Ltd. (India), GeoVax (US), Sumaya Biotech (Germany), VLP Therapeutics (US), OSIVAX (France), AJANTA PHARMA (India), Strides Pharma Science Limited (India), Mylan N.V. (US), Zydus Cadila (India), Cipla Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), Taj Pharmaceuticals Limited. (India), Lupin (India), Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Malaria is a fever illness caused by Plasmodium parasites that are transmitted to humans by mosquito bites from infected female Anopheles mosquitos. Malaria is usually treated with a single medicine as a first line of treatment, and combination drug therapy is used as a second line of treatment. Antimalarial medications are available in tablet, injectable, and capsule form. For the treatment of malarial infection, several medications such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others are available in the market.
Drivers
The rise in prevalence of malaria in low-income countries is anticipated to flourish the growth rate of the market. Malaria is a life-threatening infectious disease spread by female Anopheles mosquitoes and caused by the Plasmodium parasite. The malaria epidemic is spreading, and climate change is making it easier for mosquito vectors to thrive. According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America. In addition, malaria is most common in Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific.
Another significant factor influencing the growth rate of malaria treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the malaria treatment market. Additionally, surging number of geriatric population and rising use of insect repellent among people will result in the expansion of malaria treatment market.
Opportunities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the malaria treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the malaria treatment market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment is anticipated to obstruct the market’s growth rate. The lack of healthcare infrastructure in developing economies and strict regulatory process will challenge the malaria treatment market. Additionally, complications involved with malaria such as low blood sugar, anemia, organ failure, breathing problems, and cerebral malaria will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Middle East and Africa malaria treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa malaria treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Malaria is prevalent in hot, humid tropical settings. Every year, 2,000 people in the United States contract malaria. Malaria affects around 220 million people worldwide every year. In Africa and South Asia, the bulk of these occurrences occur. Every year, over 450,000 people suffer from the disease.
Middle East and Africa malaria treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. One of the major causes driving the expansion of the antimalarial medicine industry is the exponential increase in COVID-19 cases around the world. According to the World Health Organization's most recent data, there were around 1.8 million confirmed cases of coronavirus illness worldwide. Chloroquines can prevent the virus from infecting individuals because they can affect the pH at the cell surface. As a result, it is believed that hydroxychloroquine pills will block the virus that causes COVID-19. With an increase in COVID-19 infections around the world and hydroxychloroquine as a viable treatment, demand for antimalarial medications to combat the coronavirus may rise.
Recent Development
The Middle East and Africa malaria treatment market is segmented on the basis of diagnosis, agent, treatment, drug class, dosage form, drug type, route of administration, age group, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Agent
Treatment
Drug class
Drug Type
Diagnosis
Route of Administration
Dosage Form
Age Group
End-Users
Distribution Channel
The Middle East and Africa malaria treatment market is analysed and market size insights and trends are provided by country, diagnosis, agent, treatment, drug class, dosage form, drug type, route of administration, age group, end-users and distribution channel as referenced above.
The countries covered in the Middle East and Africa malaria treatment market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
Saudi Arabia is expected to grow at a substantial growth rate during the forecast period of 2022-2029 because of the increasing the awareness towards malaria treatment and rising level of investment by market players in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The Middle East and Africa malaria treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa malaria treatment market.
Some of the major players operating in the Middle East and Africa malaria treatment market are:
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET TYPE COVERAGE GRID
2.8 AGENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
5 PIPELINE ANALYSIS
5.1 LIST OF PIPELINE PRODUCTS
6 REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN GOVERNMENT INITIATION AND EXPENDITURE FOR PREVENTION OF MALARIA
7.1.2 HIGH PREVALENCE AND DISEASE BURDEN OF MALARIA
7.1.3 RISE IN MEDICAL INSURANCE
7.1.4 HUMID CLIMATIC CONDITIONS AND EFFICIENT MOSQUITO (ANOPHELES GAMBIAE COMPLEX) IN CERTAIN PARTS OF AFRICA
7.2 RESTRAINTS
7.2.1 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH ANTI-MALARIA DRUGS
7.2.2 LACK OF AWARENESS RELATED TO SYMPTOMS OF MALARIA
7.2.3 LOW ECONOMIC GROWTH, UNDERDEVELOPED HEALTHCARE INFRASTRUCTURE, AND LACK OF ACCESS TO ADVANCED TREATMENT
7.3 OPPORTUNITY
7.3.1 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
7.3.2 RISING PRODUCT LAUNCHES
7.3.3 INCREASE IN THE PRODUCTION AND EXPORT AS WELL AS IMPORT OF HYDROXYCHLOROQUINE AND CHLOROQUINE
7.4 CHALLENGES
7.4.1 REGULATORY CHALLENGES TO ANTIMALARIAL DRUG APPROVAL
7.4.2 ACHIEVING UNIVERSAL ACCESS
8 COVID-19 IMPACT ON MALARIA TREATMENT IN HEALTHCARE INDUSTRY
8.1 PRICE IMPACT
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY AGENT
9.1 OVERVIEW
9.2 PLASMODIUM FALCIPARUM
9.3 P. VIVAX
9.4 P. OVALE
9.5 P. MALARIAE
9.6 P. KNOWLELSI
10 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CHLOROQUINE
10.2.2 PRIMAQUINE
10.2.3 ARTEMISININ-BASED COMBINATION THERAPY (ACT)
10.2.3.1 ARTEMETHER–LUMEFANTRINE
10.2.3.2 ARTESUNATE-AMODIAQUINE
10.2.3.3 DIHYDROARTEMISININ-PIPERAQUINE
10.2.3.4 OTHERS
10.2.4 QUININE
10.2.5 HYDROXYCHLOROQUINE
10.2.6 MEFLOQUINE
10.2.7 NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS)
10.2.7.1 SULFADOXINE-PYRIMETHAMINE WITH CHLOROQUINE
10.2.7.2 SULFADOXINE-PYRIMETHAMINE WITH AMODIAQUINE
10.2.7.3 OTHERS
10.2.8 OTHERS
10.3 VACCINE
10.3.1 RTS,S/AS01
10.3.2 PFSPZ
10.3.3 OTHERS
11 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 SUPPRESSIVE TREATMENT
11.3 RADICAL TREATMENT
12 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 ARTEFAN
12.3.2 COARTEM
12.3.3 RIAMET
12.3.4 MALARONE
12.3.5 EURARTESIM
12.3.6 LONART
12.3.7 OTHERS
13 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 INTRAMUSCULAR
13.3.3 SUBCUTANEOUS
14 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACIES
15.4 RETAIL PHARMACIES
15.5 ONLINE PHARMACIES
16 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY GEOGRAPHY
16.1 MIDDLE EAST & AFRICA
16.1.1 NIGERIA
16.1.2 DEMOCRATIC REPUBLIC OF THE CONGO
16.1.3 UGANDA
16.1.4 MOZAMBIQUE
16.1.5 NIGER
16.1.6 CÔTE D’IVOIRE
16.1.7 SOUTH AFRICA
16.1.8 SAUDI ARABIA
16.1.9 UAE
16.1.10 ISRAEL
16.1.11 EGYPT
16.1.12 KUWAIT
16.1.13 REST OF MIDDLE EAST & AFRICA
17 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 AJANTA PHARMA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 NOVARTIS AG
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 CIPLA INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 STRIDES PHARMA SCIENCE LIMITED
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 HIKMA PHARMACEUTICALS PLC
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 IPCA LABORATORIES LTD.
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 MYLAN N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 ACTIZA PHARMACEUTICAL PRIVATE LIMITED
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 ADVACARE PHARMA
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 AMNEAL PHARMACEUTICALS LLC
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 BLISS GVS PHARMA LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 GEOVAX
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MMV
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 OSIVAX
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SUMAYA BIOTECH
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 TAJ PHARMACEUTICALS LIMITED
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 VLP THERAPEUTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 ZYDUS CADILA
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 3 ESTIMATED MALARIA CASES AND DEATHS BY REGION, 2018
TABLE 4 FUTURE VECTOR CARE - FUTURE GENERALI (MALARIA CARE FAMILY HEALTH PLAN)
TABLE 5 REGULATORY CHALLENGES TO ANTIMALARIAL DRUG APPROVAL.
TABLE 6 CHALLENGES AND PROBLEMS THAT DRIVE THE R&D FRAMEWORK
TABLE 7 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY AGENT 2019-2027 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA PLASMODIUM FALCIPARUM IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA P. VIVAX IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA P. OVALE IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA P. MALARIAE IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA P. KNOWLELSI IN MALARIA TREATMENT MARKET, BY MONTH 2018-2027 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TYPE 2019-2027 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA VACCINE IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE 2019-2027 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA SUPPRESSIVE TREATMENT IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA RADICAL TREATMENT IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE 2019-2027 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA GENERICS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ORAL IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY END USER 2019-2027 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA HOSPITALS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2019-2027 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA DIRECT TENDER IN MALARIA TREATMENT MARKET, BY REGION, 2017-2027 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN MALARIA TREATMENT MARKET, BY REGION, 2018-2027 (USD THOUSAND)
TABLE 41 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY REGION 2018-2027 (USD THOUSAND)
TABLE 42 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 43 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 44 MIDDLE EAST & AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 45 MIDDLE EAST & AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 46 MIDDLE EAST & AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 47 MIDDLE EAST & AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 48 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 49 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 50 MIDDLE EAST & AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 51 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 52 MIDDLE EAST & AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 53 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 54 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 55 NIGERIA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 56 NIGERIA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 57 NIGERIA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 58 NIGERIA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 59 NIGERIA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 60 NIGERIA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 61 NIGERIA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 62 NIGERIA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 63 NIGERIA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 64 NIGERIA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 65 NIGERIA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 66 NIGERIA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 67 NIGERIA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 68 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 69 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 70 DEMOCRATIC REPUBLIC OF THE CONGO MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 71 DEMOCRATIC REPUBLIC OF THE CONGO ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 72 DEMOCRATIC REPUBLIC OF THE CONGO NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 73 DEMOCRATIC REPUBLIC OF THE CONGO VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 74 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 75 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 76 DEMOCRATIC REPUBLIC OF THE CONGO BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 77 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 78 DEMOCRATIC REPUBLIC OF THE CONGO PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 79 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 80 DEMOCRATIC REPUBLIC OF THE CONGO MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 81 UGANDA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 82 UGANDA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 83 UGANDA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 84 UGANDA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 85 UGANDA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 86 UGANDA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 87 UGANDA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 88 UGANDA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 89 UGANDA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 90 UGANDA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 91 UGANDA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 92 UGANDA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 93 UGANDA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 94 MOZAMBIQUE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 95 MOZAMBIQUE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 96 MOZAMBIQUE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 97 MOZAMBIQUE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 98 MOZAMBIQUE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 99 MOZAMBIQUE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 100 MOZAMBIQUE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 101 MOZAMBIQUE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 102 MOZAMBIQUE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 103 MOZAMBIQUE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 104 MOZAMBIQUE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 105 MOZAMBIQUE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 106 MOZAMBIQUE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 107 NIGER MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 108 NIGER MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 109 NIGER MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 110 NIGER ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 111 NIGER NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 112 NIGER VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 113 NIGER MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 114 NIGER MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 115 NIGER BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 116 NIGER MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 117 NIGER PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 118 NIGER MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 119 NIGER MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 120 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 121 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 122 CÔTE D’IVOIRE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 123 CÔTE D’IVOIRE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 124 CÔTE D’IVOIRE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 125 CÔTE D’IVOIRE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 126 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 127 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 128 CÔTE D’IVOIRE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 129 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 130 CÔTE D’IVOIRE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 131 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 132 CÔTE D’IVOIRE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 133 SOUTH AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 134 SOUTH AFRICA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 135 SOUTH AFRICA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 136 SOUTH AFRICA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 137 SOUTH AFRICA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 138 SOUTH AFRICA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 139 SOUTH AFRICA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 140 SOUTH AFRICA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 141 SOUTH AFRICA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 142 SOUTH AFRICA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 143 SOUTH AFRICA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 144 SOUTH AFRICA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 145 SOUTH AFRICA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 146 SAUDI ARABIA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 147 SAUDI ARABIA MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 148 SAUDI ARABIA MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 149 SAUDI ARABIA ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 150 SAUDI ARABIA NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 151 SAUDI ARABIA VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 152 SAUDI ARABIA MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 153 SAUDI ARABIA MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 154 SAUDI ARABIA BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 155 SAUDI ARABIA MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 156 SAUDI ARABIA PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 157 SAUDI ARABIA MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 158 SAUDI ARABIA MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 159 UAE MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 160 UAE MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 161 UAE MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 162 UAE ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 163 UAE NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 164 UAE VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 165 UAE MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 166 UAE MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 167 UAE BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 168 UAE MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 169 UAE PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 170 UAE MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 171 UAE MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 172 ISRAEL MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 173 ISRAEL MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 174 ISRAEL MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 175 ISRAEL ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 176 ISRAEL NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 177 ISRAEL VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 178 ISRAEL MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 179 ISRAEL MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 180 ISRAEL BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 181 ISRAEL MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 182 ISRAEL PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 183 ISRAEL MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 184 ISRAEL MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 185 EGYPT MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 186 EGYPT MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 187 EGYPT MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 188 EGYPT ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 189 EGYPT NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 190 EGYPT VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 191 EGYPT MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 192 EGYPT MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 193 EGYPT BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 194 EGYPT MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 195 EGYPT PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 196 EGYPT MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 197 EGYPT MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 198 KUWAIT MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
TABLE 199 KUWAIT MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 200 KUWAIT MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 201 KUWAIT ARTEMISININ-BASED COMBINATION THERAPY (ACT) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 202 KUWAIT NON-ARTEMISININ BASED COMBINATIONS (NON-ACTS) MEDICATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 203 KUWAIT VACCINATION IN MALARIA TREATMENT MARKET, BY TYPE, 2018-2027 (USD THOUSAND)
TABLE 204 KUWAIT MALARIA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2027 (USD THOUSAND)
TABLE 205 KUWAIT MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 206 KUWAIT BRANDED IN MALARIA TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD THOUSAND)
TABLE 207 KUWAIT MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 208 KUWAIT PARENTERAL IN MALARIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD THOUSAND)
TABLE 209 KUWAIT MALARIA TREATMENT MARKET, BY END USER 2018-2027 (USD THOUSAND)
TABLE 210 KUWAIT MALARIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSAND)
TABLE 211 REST OF MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET, BY AGENT, 2018-2027 (USD THOUSAND)
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: MARKET TYPE COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASE IN GOVERNMENT INITIATION AND EXPENDITURE FOR PREVENTION OF MALARIA IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET IN 2020 & 2027
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET
FIGURE 14 THE U.S. FUNDING FOR MIDDLE EAST AND AFRICA MALARIA, FY 2001 –2021
FIGURE 15 MALARIA CASES IN THE 10 HIGHEST BURDEN COUNTRIES IN AFRICA, 2010-2017
FIGURE 16 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, 2019
FIGURE 17 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, 2019-2027 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, CAGR (2020-2027)
FIGURE 19 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY AGENT, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, 2019
FIGURE 21 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, 2019-2027 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 23 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, 2019
FIGURE 25 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, 2019-2027 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2020-2027)
FIGURE 27 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, 2019
FIGURE 29 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, 2019-2027 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)
FIGURE 31 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019
FIGURE 33 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019-2027 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)
FIGURE 35 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, 2019
FIGURE 37 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, 2019-2027 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, CAGR (2020-2027)
FIGURE 39 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 41 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSAND)
FIGURE 42 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 43 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: SNAPSHOT (2019)
FIGURE 45 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2019)
FIGURE 46 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2020 & 2027)
FIGURE 47 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY COUNTRY (2019 & 2027)
FIGURE 48 MIDDLE EAST & AFRICA MALARIA TREATMENT MARKET: BY TYPE (2020-2027)
FIGURE 49 MIDDLE EAST AND AFRICA MALARIA TREATMENT MARKET: COMPANY SHARE 2019 (%)
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.